RALEIGH, N.C., March 5, 2014 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced that Dr. Mark A. Sirgo, President and Chief Executive Officer of BDSI, will present at the 26 th Annual ROTH Conference. The presentation is scheduled for Monday, March 10, 2014 at 8:00 a.m. Pacific Time ( 11:00 a.m. Eastern Time) at the Ritz Carlton, Laguna Niguel in Dana Point, California.
The New Drug Application (NDA) for BUNAVAIL for the treatment of opioid dependence is currently under review by the U.S. Food and Drug Administration (FDA), and based on timelines established by the Prescription Drug User Fee Act (PDUFA), the review of the BUNAVAIL NDA is expected to be completed by June 7, 2014.
Dr. Sirgo will be providing an update on BUNAVAIL commercial options and the anticipated market opportunity as well as the progress made by BDSI and its commercial partner, Endo Pharmaceuticals, with the ongoing Phase 3 clinical program for BEMA Buprenorphine for the treatment of chronic pain. The update will include the recently announced positive topline results from the Phase 3 clinical study of BEMA Buprenorphine in opioid naïve patients.
The presentation will be webcast live and can be accessed at www.bdsi.com. For those who are not available to listen to the live broadcast, a replay of the webcast will be available on the BDSI website.About BioDelivery Sciences International BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.